Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Volume 3, Issue 5, Pages (May 2001)
Volume 8, Issue 1, Pages (July 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
The Mre11 Complex Is Required for Repair of Hairpin-Capped Double-Strand Breaks and Prevention of Chromosome Rearrangements  Kirill S. Lobachev, Dmitry.
Isothermal Multiple Displacement Amplification
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors by Clemens-Martin Wendtner, David.
Levels of Polyadenylation Factor CstF-64 Control IgM Heavy Chain mRNA Accumulation and Other Events Associated with B Cell Differentiation  Yoshio Takagaki,
Molecular Therapy - Methods & Clinical Development
Volume 10, Issue 4, Pages (October 2004)
Robert E. White, Richard Wade-Martins, Michael R. James 
Volume 16, Issue 3, Pages (March 2008)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Volume 101, Issue 5, Pages (May 2000)
Improved system for helper-dependent adenoviral vector production
Claire Soudais, Sylvie Boutin, Eric J. Kremer  Molecular Therapy 
Volume 4, Issue 6, Pages (December 2001)
Volume 2, Issue 4, Pages (October 2000)
Volume 2, Issue 5, Pages (November 2000)
Volume 9, Issue 6, Pages (June 2004)
Volume 6, Issue 2, Pages (August 2002)
Volume 61, Issue 1, Pages S9-S15 (January 2002)
Volume 10, Issue 1, Pages (July 2004)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Molecular Therapy - Methods & Clinical Development
Volume 11, Issue 2, Pages (February 2005)
Vaccinia virus as a subhelper for AAV replication and packaging
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors  Mohammad H. Eslami, MD, Sidhu P. Gangadharan, MD,
Volume 12, Issue 6, Pages (December 2005)
Volume 2, Issue 3, Pages (September 2000)
Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector  Donna J Palmer, Nathan.
Volume 5, Issue 2, Pages (February 2002)
A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors  Qizhao Wang, Zhongren Wu, Junping Zhang, Jenni Firrman, Hongying Wei, Zhengjing.
Volume 17, Issue 2, Pages (February 2009)
Volume 19, Issue 3, Pages (March 2011)
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Volume 8, Issue 4, Pages (October 2003)
Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury  Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.
Richard A Voit, Moira A McMahon, Sara L Sawyer, Matthew H Porteus 
Adenovirus Virion Stability and the Viral Genome: Size Matters
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles
Volume 16, Issue 5, Pages (May 2008)
Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base  Siobhan M Cashman,
Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley  Molecular Therapy 
Volume 22, Issue 4, Pages (April 2014)
Volume 6, Issue 3, Pages (September 2002)
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 4, Issue 6, Pages (December 2001)
Volume 6, Issue 3, Pages (September 2002)
Volume 11, Issue 2, Pages (February 2005)
Volume 10, Issue 6, Pages (December 2004)
A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High-titer rAAV Stocks From Insect Cells  Richard.
Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes  Zekun Wang, Fang Cheng, John F. Engelhardt,
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Volume 7, Issue 1, Pages (January 2003)
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
Volume 9, Issue 4, Pages (April 2004)
Volume 11, Issue 5, Pages (May 2005)
Meiotic DNA Breaks at the S. pombe Recombination Hot Spot M26
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
Volume 3, Issue 4, Pages (April 2001)
Volume 14, Issue 1, Pages (July 2006)
Marc-André Langlois, Nan Sook Lee, John J Rossi, Jack Puymirat 
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Generation of Recombinant Adeno-associated Virus Vectors by a Complete Adenovirus- Mediated Approach  Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy  Volume 3, Issue 5, Pages 787-792 (May 2001) DOI: 10.1006/mthe.2001.0306 Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 1 A strategy for the production of rAAV vectors based on the exclusive use of adenovirus vectors. (A) A schematic drawing of adenovirus-based production of recombinant rAAV. ITR, inverted terminal repeat sequence of AAV. g.o.i, gene of interest. IP, inducible promoter. CMV, cytomegalovirus promoter. (B) The three adenovirus vectors to be used for the production of rAAV-CMVGFP by use of a tetracycline-inducible system for rep production. GFP, green fluorescence protein. The arrows on top of the bars, which represent coding sequences of genes, indicate promoters. AAVpA, AAV polyadenylation signal. SV40pA, SV40 polyadenylation signal. X represents mutations that disrupt the p40 promoter. Molecular Therapy 2001 3, 787-792DOI: (10.1006/mthe.2001.0306) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 2 Characterization of the AdTRErepCMVcap. (A) Western blot analysis of adenovirus-directed expression of cap and rep genes. Left shows constitutive cap gene expression in 293 cells with increasing doxycycline. Right shows inducible rep78/68 gene expression with increasing dox concentration. In the control, a low but significant background is present. This is consistent with earlier reports about the tet-ON system (31, 32). Please also notice the constitutive level of rep52/40. (B) H/ndMI digestion of AdTRErepCMVcap DNA from serially passaged virus preparations. DNA in each lane was derived by proteinase K digestion of 1012 virus particles and phenol-chloroform extraction. A 1-kb DNA marker (Life Technologies, Bethesda, MD) was used for size determination. The number on top of each lane represents passage number. Molecular Therapy 2001 3, 787-792DOI: (10.1006/mthe.2001.0306) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 3 Production and analysis of rAAVCMVGFP by use of the tetracycline-inducible three-vector adenovirus system. (A) The titers of rAAVCMVGFP produced with different concentrations of doxycycline (determined by GFP fluorescence microscopy, as described under Experimental Protocols). (B) A photograph showing a clear rAAVCMVGFP band (prepared from five 150-mm petri dishes of 293 cells) that has been centrifuged and stained with ethidium bromide (33). (C) A Southern blot analysis of extrachromosomal DNA (isolated by the Hirt (23) method) to detect monomeric and dimeric forms of replicating AAV genomes. Two Hirt DNA samples were obtained. The first sample was derived from infecting 293 cells with the recombinant rAAVCMVGFP particles isolated from our tri-adenovirus approach together with a wild-type adenovirus. The second sample was derived from infecting 293 cells with wild-type AAV particles and wild-type adenovirus. The Hirt DNA samples were isolated 48 h postinfection. Duplicate Southern blots were carried out to obtain two membranes with the same two samples. The two membranes were then probed with two separate probes. The first is an EGFP fragment from pEGFP-N1 (Clontech). The second is a 1.2-kb rep fragment derived by restriction digestion (NcoI and HindIII). In both blots, the monomeric (MMF) and the dimeric (DMF) forms of the replicating AAV genomes are clearly visible. Left: Results from GFP probe. Right: Results from the rep probe. (D) Replication center assay of the rAAVCMVGFP. Top filter, 32P-labeled EGFP was used to hybridize with rAAVCMVGFP- and AdTRErepCMVcap-infected 293 cells. About 104 total virus particles of rAAVCMVGFP was used to infect the cells. Lower filter, 32P-labeled rep fragment was used to hybridize with rAAV-GFP- and wild-type Ad5 virus-infected 293 cells. About 1010 total rAAVCMVGFP particles were used to infect 293 cells. Each of the black dots in the top filter represents an active rAAV particle with the EGFP gene. The absence of any visible signal in the lower filter indicates a lack of active virus particles with the rep gene (which should be carried by the wild-type AAV virus). Molecular Therapy 2001 3, 787-792DOI: (10.1006/mthe.2001.0306) Copyright © 2001 American Society for Gene Therapy Terms and Conditions